Immuron (IMRN) vs Alaunos Therapeutics (TCRT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immuron is the larger company by market cap ($7.3 million vs $7.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRN | TCRT |
|---|---|---|
| Share price | $0.8998 | $1.66 |
| Market cap | $7.26M | $6.99M |
| 1-day change | +5.80% | +3.75% |
| EPS (TTM) | $-0.34 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.00K |
| Revenue growth (YoY) | — | -50.00% |
| Net income (latest FY) | — | $-4.18M |
| Operating margin | — | -84500.00% |
| Net margin | — | -83520.00% |
| 52-week high | $1.99 | $4.50 |
| 52-week low | $0.677 | $0.72 |
| Distance from 52-week high | -54.78% | -63.11% |
| Analyst consensus | none | — |
| Avg. price target upside | +332.32% | — |
| Average volume | 2.06M | 7.56M |
| Shares outstanding | 8.07M | 4.21M |
| Employees | 7 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Alaunos Therapeutics
TCRT stock →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
IMRN vs TCRT FAQ
Which is bigger, Immuron or Alaunos Therapeutics?
Immuron (IMRN) is larger, with a market capitalization of $7.26M compared with $6.99M for Alaunos Therapeutics (TCRT).
Are Immuron and Alaunos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.